Related Experiment Video

Updated: May 30, 2026

Measuring Psoriasis Severity at Home
02:28

Measuring Psoriasis Severity at Home

Published on: March 1, 2024

Attributable risk estimate of severe psoriasis on major cardiovascular events

Nehal N Mehta1, YiDing Yu, Rebecca Pinnelas

  • 1Preventive Cardiology, Division of Cardiovascular Medicine, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, USA. Nehal.Mehta@uphs.upenn.edu

The American Journal of Medicine
|July 27, 2011
PubMed

Insights

Severe psoriasis significantly increases the risk of major adverse cardiac events. Patients with severe psoriasis face an additional 6.2% risk over 10 years, highlighting the need for cardiovascular monitoring.

Area of Science:

  • Cardiology
  • Dermatology
  • Epidemiology

Background:

  • Psoriasis, especially severe cases, is increasingly linked to cardiovascular disease.
  • Major adverse cardiac events (MACE) include heart attack, stroke, and cardiovascular mortality.
  • Understanding the attributable risk of psoriasis to MACE is crucial for public health.

Purpose of the Study:

  • To compare MACE risk in psoriasis patients versus the general population.
  • To quantify the attributable risk of severe psoriasis for MACE.
  • To inform cardiovascular risk stratification in severe psoriasis patients.

Main Methods:

  • A cohort study utilizing the General Practice Research Database.
  • Severe psoriasis defined by diagnosis and systemic therapy (N=3603).
  • Matched controls (N=14,330) selected from the same practices.

Main Results:

  • Severe psoriasis is a significant risk factor for MACE (HR 1.53; 95% CI, 1.26-1.85).
  • Adjusted analysis accounted for age, gender, diabetes, hypertension, smoking, and hyperlipidemia.
  • Severe psoriasis adds 6.2% absolute risk of 10-year MACE.

Conclusions:

  • Severe psoriasis increases 10-year MACE risk by 6.2% compared to the general population.
  • Findings suggest implications for cardiovascular risk management in severe psoriasis.
  • Further prospective studies are recommended for validation.
Abstract

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Related Concept Videos

Relative Risk01:12

Relative Risk

Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...